Evaluation Of TLR-4 Level Among Pfizer/Biontech Vaccinated People

Abstract

Background: Over 221 million illnesses and over 4.6 million fatalities caused by the coronavirus disease 2019 (COVID-19) were confirmed as of September 2021, according to the WHO. Accelerated vaccine development initiatives and widespread immunization campaigns were implemented to address the enormous morbidity and death load. The most reliable approach to stop the spread of infectious illnesses is through vaccination. Methods: The study had eighty-one (81) participants ranging from 18 to 66 years old who were recently injected with COVID-19 mRNA Pfizer/BioNTech [BNT162b2] vaccines. They received two vaccine doses of 30 µg, 0.3 mL injections twenty-one (21) days apart. Before the first vaccination, blood samples were collected. This procedure was repeated on days 7-10 following the first immunization, and on 7–10 days following the second dosage. All samples were tested for TLR-4 using a High Sensitivity Human ELISA Kit (Elabscience/United State). Results: TLR-4 levels did not significantly rise in any of the groups. Conclusions: The elevated TLR-4, was not significantly rise in any of the studied groups of our study. Further clinical studies are needs to understand the role of other immunological factors in safety of COVID-19 vaccines.